Nahyan bin Mubarak Inaugurates World Tolerance Summit in Dubai
His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Chairman of the Board of Trustees of the International Institute for Tolerance, IIT, officially opened on Thursday the second day of the second World Tolerance Summit (WTS), held this year under the theme ‘Tolerance in Multiculturalism: Achieving the Social, Economic and Humane Benefits of a Tolerant World'. Over 3,000 participants from over 100 countries and 70 speakers from around the world took part in the summit, organized by the International Institute for Tolerance (IIT), part of the Mohammed bin Rashid Al Maktoum Global Initiatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005620/en/
HE Sheikh Nahyan bin Mubarak Al Nahyan touring the WTS collocating exhibition, accompanied by Dawood Al Shezawi, Chairman of the Organizing Committee of the WTS (right) and HE Sheikh Abdulla bin Bayyah, Chairman of the UAE Fatwa Council, and HE Rustem Nurgalevich Menekhanov, President of the Republic of Tatarstan (left). (Photo : AETOSWire)
The event featured a set of interactive sessions and workshops, focused on four themes: economic, social, cultural and media tolerance. It aims to promote peaceful coexistence, mutual respect, acceptance of others and to achieve friendly ties between people, regardless of their faiths, beliefs, cultures and languages.
The special ceremony, held at Madinat Jumeirah Conference & Events Centre in Dubai, opened with the launch of a video titled ‘Humanity and Access to a Tolerant World’, which underlined the instrumental role of tolerance in promoting world peace and security. In his address to attendees, HE Sheikh Nahyan bin Mubarak Al Nahyan said that the summit, graced by the generous patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President and Prime Minister, and Ruler of Dubai, serves as a prestigious global platform for dialogue and joint action to achieve wellbeing for all.
He said: “The summit complements the UAE's efforts to serve society and human beings in the region and the world.” Quoting His Highness Sheikh Mohammed, he added: “What makes us proud of our nation is not the height of our buildings, the breadth of our streets, or the magnitude of our shopping malls, but rather the openness and tolerance of our nation.”
The event included dialogue sessions, workshops and a specialized digital library with more than 80 specialized publications and researches. It featured 36 student projects from 16 local and international universities, and an exhibition that saw participation from over 35 local and international government entities, showcasing their practices and programs to spread the values of tolerance, justice and equality.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005620/en/
Contact information
Strategic Marketing and Exhibitions
Nazeem Beegum,
Public Relations Officer, T: +97143285799, M: +971564034049
nazeem.beegum@strategic.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom